News

The drug is being developed for the treatment of patients with relapsed/refractory and frontline intermediate or high-risk AML and is currently been evaluated in multiple Phase II clinical

At present, there is no approved antidote to treat these patients and andexanet alfa has the potential to become the first approved universal antidote for Factor Xa inhibitors

Kyprolis is a product of Amgen’s subsidiary Onyx Pharmaceuticals, which holds global development and commercialization rights to the product, excluding Japan. Onyx Pharmaceuticals president Pablo Cagnoni said: "Achieving

The new indication for Eylea includes macular edema following branch retinal vein occlusion (BRVO) in addition to the previously-approved indication of macular edema secondary to central retinal vein

Acceliant platforms offer smooth execution of clinical data management activities such as database design, UAT and several report formats for business intelligence. These platforms give Lupin a collaborative

A calcimimetic agent administered intravenously, AMG 416 binds to and activates the calcium-sensing receptor on the parathyroid gland, thereby reducing serum intact PTH levels. The randomized, active-controlled, double-blind,

The company’s HMC technology introduces a new era of cell therapy for ophthalmic, autoimmune and inflammatory diseases. According to the company, this development allows the generation of a

In the trial, eribulin showed a statistically significant extension in overall survival (OS) over the comparator treatment dacarbazine, the primary endpoint of the study. The company said that

The drug is also indicated to treat pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. Owned by Actavis, Avycaz is a combination of a